Q3 Loss Widens to $62.4M on Former-CEO Stock Comp; $481.6M Cash Funds Runway Into 2029
MBX has more than doubled off its 52-week low of $21.9.
Summary
MBX posted a $62.4M Q3 net loss versus $21.6M a year ago, but $20.8M of that gap is a one-time stock-comp modification for the former CEO that pushed G&A to $34.3M from $4.7M. R&D rose to $32.0M from $19.3M as the canvuparatide Phase 3 oPTimize trial started up. Cash and investments stand at $481.6M after $97.6M of net ATM proceeds, enough to fund operations into 2029 — no near-term financing need. The operational news is the timeline: first patient dosed in the pivotal Phase 3 in August, and unblinded 12-week MAD data for once-monthly obesity candidate MBX 4291 still on track for Q4 2026. Preclinical MBX 6180 data will be presented at ObesityWeek, November 14-17, 2026.
At the time of this announcement, MBX was trading at $53.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $21.90 to $72.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.